A 32-year-old woman in Mumbai has been using combined oral contraceptive pills for 5 years without complications. She asks about the most common metabolic side effect associated with long-term OCP use. What is the most frequent metabolic change observed?

Explanation

## Most Common Metabolic Side Effect of OCPs **Key Point:** Increase in serum triglycerides is the most common and most clinically significant metabolic change associated with long-term combined oral contraceptive use. ### Mechanism of Hypertriglyceridemia with OCPs 1. **Estrogen-induced hepatic lipase suppression** — Estrogen reduces hepatic lipase activity, which normally catabolizes triglyceride-rich lipoproteins 2. **Increased VLDL production** — Estrogen stimulates hepatic synthesis of very-low-density lipoprotein (VLDL) 3. **Dose-dependent effect** — Higher estrogen doses cause greater triglyceride elevation 4. **Progestin modulation** — Androgenic progestins (e.g., levonorgestrel) may partially offset estrogen effects ### Magnitude of Change - **Average increase:** 20–30% elevation in serum triglycerides - **Range:** Can increase by 10–50% depending on baseline lipid profile and pill formulation - **Clinical significance:** Becomes important in women with baseline hypertriglyceridemia (>150 mg/dL) ### Lipid Profile Changes with OCPs | Lipid Parameter | Change | Magnitude | Clinical Significance | |---|---|---|---| | **Triglycerides** | ↑ | +20–30% | Most common; dose-dependent | | Total cholesterol | ↑ | +5–10% | Modest; mainly LDL | | LDL cholesterol | ↑ | +5–15% | Variable | | HDL cholesterol | ↑ or ↓ | ±5–10% | Depends on progestin type | | VLDL | ↑ | +15–25% | Secondary to TG increase | **High-Yield:** In women with baseline triglycerides >250 mg/dL or familial hypertriglyceridemia, OCPs are relatively contraindicated due to risk of acute pancreatitis. ### Clinical Pearl **Estrogen dose is the primary driver of triglyceride elevation.** Modern ultra-low-dose pills (20 µg ethinyl estradiol) cause less triglyceride elevation than standard-dose pills (30–35 µg). Progestin choice also matters: desogestrel and norgestimate may have more favorable lipid profiles than levonorgestrel. ### Management Strategy - **Baseline lipid screening** before starting OCPs in women with family history of dyslipidemia - **Repeat lipid panel** at 3–6 months if baseline triglycerides are elevated - **Switch to ultra-low-dose estrogen** or **progestin-only methods** if triglycerides rise significantly - **Lifestyle modification** (diet, exercise) as first-line intervention **Tip:** When counselling women starting OCPs, mention that triglyceride elevation is common but usually mild and often asymptomatic. Baseline lipid screening is important in those with risk factors.